Moreover, Franko-Tobin et al. suggested that valproic acid suppresses cervical cancer cell growth and promotes the expression of Notch1 and somatostatin receptor subtype 2 (SSTR2), while its combination with the SSTR2-targeting cytotoxic conjugate camptothecin-somatostatin (CPT-SST) correlates with elevated therapeutic potency [87]. The gene discussed is SSTR2; the disease is cervical carcinoma.